CoChat
Sign Up
Cited by 52Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Assessing risk for preclinical β‐amyloid pathology with APOE , cognitive, and demographic information

Open access
Insel, Philip S., Palmqvist, Sebastian, Mackin, R. Scott, Nosheny, Rachel L., Hansson, Oskar, Weiner, Michael W., Mattsson, Niklas, Alzheimer's Disease Neuroimaging Initiative·2016·Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
DOI 10.1016/j.dadm.2016.07.002PMC PMC5045949
Open this paper in CoChat — free accountOpen PDF

Abstract

Introduction: Clinical trials in Alzheimer's disease are aimed at early stages of disease, including preclinical Alzheimer's disease. The high cost and time required to screen large numbers of participants for Aβ pathology impede the development of novel drugs. This study's objective was to evaluate the extent to which inexpensive and easily obtainable information can reduce the number of screen failures by increasing the proportion of Aβ+ participants identified for screening. Methods: We used random forest models to evaluate the positive predictive value of demographics, APOE , and longitudinal cognitive rates in the prediction of amyloid pathology, measured by florbetapir PET or cerebrospinal fluid. Results: Predicting Aβ positivity with demographic, APOE , and cognitive information yielded a positive predictive value estimate of 0.65 (95% CI, 0.50–0.96), nearly a 60% increase over the reference Aβ+ prevalence in the cohort of 0.41. Conclusions: By incorporating this procedure, clinical trial screening costs may be substantially reduced.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.dadm.2016.07.002

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The participants in this study were relatively young (average age 65 years) compared to ADNI and BioFinder cohorts.

    “According to our inclusion criteria, the participants in this study were relatively young (average age: 65 years) comparing to ADNI and BioFinder cohorts11,40,41.”

    From Integrated algorithm combining plasma biomarkers and cognitive assessments accurately predicts brain β-amyloid pathology (2023) · cites this paper as [40]

    The Methods (Participants) identify this as an ADNI study, and the Results report a mean age of 78.1 years for a model-selected subgroup, which is older than the citing study’s stated average of 65. That figure is not the mean for the full ADNI cohort, and the paper provides no BioFinder age comparison. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 23

  1. [2]Sperling R.A. Rentz D.M. Johnson K.A. Karlawish J. Donohue M. Salmon D.P. The A4 study: stopping AD before symptoms begin? Sci Transl Med 6 2014 228fs13 PMC4049292 24648338
  2. [3]Jansen W.J. Ossenkoppele R. Knol D.L. Tijms B.M. Scheltens P. Verhey F.R. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis JAMA 313 2015 1924 1938 25988462 PMC4486209
  3. [4]Rowe C.C. Ellis K.A. Rimajova M. Bourgeat P. Pike K.E. Jones G. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 31 2010 1275 1283 20472326
  4. [5]Clifford J.R. Wiste H.J. Weigand S.D. Rocca W.A. Knopman D.S. Mielke M.M. Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study Lancet Neurol 13 2014 997 1005 25201514 PMC4324499
  5. [7]Clifford J.R. Wiste H.J. Weigand S.D. Knopman D.S. Vemuri P. Mielke M.M. Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span JAMA Neurol 72 2015 511 519 25775353 PMC4428984
  6. [8]Pike K.E. Ellis K.A. Villemagne V.L. Good N. Chételat G. Ames D. Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study Neuropsychologia 49 2011 2384 2390 21529702
  7. [9]Insel P.S. Mattsson N. Mackin R.S. Kornak J. Nosheny R. Tosun Turgut D. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease Ann Clin Transl Neurol 2 2015 534 547 26000325 PMC4435707
  8. [10]Landau S.M. Mintun M.A. Joshi A.D. Koeppe R.A. Petersen R.C. Aisen P.S. Amyloid deposition, hypometabolism, and longitudinal cognitive decline Ann Neurol 72 2012 578 586 23109153 PMC3786871
  9. [11]Doraiswamy P.M. Sperling R.A. Coleman R.E. Johnson K.A. Reiman E.M. Davis M.D. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: A multicenter study Neurology 79 2012 1636 1644 22786606 PMC3468774
  10. [13]Hedden T. Oh H. Younger A.P. Patel T.A. Meta-analysis of amyloid-cognition relations in cognitively normal older adults Neurology 80 2013 1341 1348 23547267 PMC3656457
  11. [14]Rattanabannakit C. Risacher S.L. Gao S. Lane K. Brown S.A. McDonald B.C. The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests J Alzheimers Dis 51 2016 1145 1155 26923008 PMC4833578
  12. [16]Olsson A. Vanderstichele H Andreasen N. De Meyer G. Wallin A. Holmberg B. Simultaneous measurement of β-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology Clin Chem 51 2005 336 345 15563479
  13. [20]Rosen W.G. Mohs R.C. Davis K.L. A new rating scale for Alzheimer's disease Am J Psychiatry 141 1984 1356 1364 6496779
  14. [21]Insel P. Mattsson N. Donohue M.C. Mackin R.S. Aisen P.S. Jack C.R. The transitional association between β-amyloid pathology and regional brain atrophy Alzheimers Dement 10 2014 P837 P838 PMC4461550 25499535
  15. [22]Insel P.S. Mattsson N. Mackin R.S. Schöll M. Nosheny R.L. Tosun D. Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology Neurology 86 2016 1887 1896 27164667 PMC4873684
  16. [23]Mattsson N. Insel P.S. Nosheny R. Tosun D. Trojanowski J.Q. Shaw L.M. Emerging β-amyloid pathology and accelerated cortical atrophy JAMA Neurol 71 2014 725 734 24781145 PMC4410966
  17. [24]Villeneuve S. Rabinovici G.D. Cohn-Sheehy B.I. Madison C. Ayakta N. Ghosh P.M. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation Brain 138 2015 2020 2033 25953778 PMC4806716
  18. [25]Hastie T.J. Tibshirani R.J. Generalized additive models vol. 43 1990 CRC Press London
  19. [27]Blennow K. Mattsson N. Schöll M. Hansson O. Zetterberg H. Amyloid biomarkers in Alzheimer's disease Trends Pharmacol Sci 36 2015 297 309 25840462
  20. [28]Gao S. Hendrie H.C. Hall K.S. Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis Arch Gen Psychiatry 55 1998 809 815 9736007
  21. [29]Viña J. Lloret A. Why women have more Alzheimer's disease than men: gender and mitochondrial toxicity of amyloid-beta peptide J Alzheimers Dis 20 Suppl 2 2010 S527 S533 20442496
  22. [30]Stern Y. Alexander G.E. Prohovnik I. Mayeux R. Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease Ann Neurol 32 1992 371 375 1416806
  23. [33]Chételat G. La Joie R. Villain N. Perrotin A. de La Sayette V. Eustache F. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease Neuroimage Clin 2 2013 356 365 24179789 PMC3777672

Cited by

Sorted by citations

Authors
Insel, P. S., Palmqvist, S., Mackin, R. S., Nosheny, R. L., Hansson, O., Weiner, M. W., Mattsson, N., & Initiative, A. D. N.
Affiliations
  • San Francisco VA Medical Center (US)
  • Lund University (SE)
Corresponding author
Insel, Philip S.
ORCID
Venue
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Publisher
Wiley
Published
2016-01
Volume
4
Issue
1
Pages
76-84
ISSN
2352-8729 (ISSN-L)
DOI
10.1016/j.dadm.2016.07.002
PMC
PMC5045949
OpenAlex
W2480170620
Cited by
52
References
6
Citations by year
2026: 1 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 9 · 2020: 11 · 2019: 6 · 2018: 9 · 2017: 3 · 2016: 1
FWCI
5.63
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • National Institutes of Health (U01 AG024904, P30 AG010129)
  • National Institute on Aging
  • National Institute of Biomedical Imaging and Bioengineering
  • Vetenskapsrådet
  • Greta och Johan Kocks stiftelser
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
preclinical Alzheimer's disease, amyloid-beta pathology, apolipoprotein E, cognitive screening, florbetapir PET, cerebrospinal fluid amyloid, risk prediction, positive predictive value, clinical trial screening, screening cost reduction, demographic factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review